Drug profile

The FDA adverse-event record for Hydrochlorothiazide

27 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Hydrochlorothiazide. See the species affected, top reactions, and outcomes below.

27
adverse-event reports
14.8%
death-coded share
Human
most-reported species
10
Accidental exposure - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
4
Deaths Reported
14.8%
Death Rate

Active Ingredients

Hydrochlorothiazide

Administration Routes

OralUnknown

Species Affected

Human 19
Dog 8

Most Affected Breeds

Unknown 19
Maltese 1
Terrier - Fox Wire 1
Terrier - Jack Russell 1
Retriever - Labrador 1
Papillon - Spaniel - Continental Toy (with erect ears or with dropped ears (Phaléne)) 1
Chihuahua 1
Terrier (unspecified) 1
Dog (unknown) 1

Most Reported Reactions

Accidental exposure 10
Other abnormal test result NOS 7
Hyperglycaemia 4
Elevated serum alkaline phosphatase (SAP) 3
Weakness 3
Weight loss 3
Vomiting 3
Glucosuria 3
Intentional misuse 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Injection site swelling 2
Death by euthanasia 2

Outcome Breakdown

Outcome Unknown
9 (33.3%)
Recovered/Normal
8 (29.6%)
Ongoing
4 (14.8%)
Recovered with Sequela
2 (7.4%)
Euthanized
2 (7.4%)
Died
2 (7.4%)

Hydrochlorothiazide Adverse Event Insights

27 reports name Hydrochlorothiazide; 4 recorded a death outcome (14.8% of reported events, not a population-level mortality rate). Active ingredient: Hydrochlorothiazide. Administration routes: Oral, Unknown.

By species: Human (19 reports), Dog (8 reports). By breed: Unknown (19), Maltese (1), Terrier - Fox Wire (1).

Leading clinical signs: Accidental exposure (10), Other abnormal test result NOS (7), Hyperglycaemia (4), Elevated serum alkaline phosphatase (SAP) (3). Outcome, 27 coded reports: Outcome Unknown leads at 33.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.